课题基金 / 基金详情

Staff Investigators

Staff Investigators
职员调查员
批准号：
7529414
负责人：
FRANK M. TORTI
金额：
$4.58万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-07-11 至 2012-01-31
来源：
https://reporter.nih.gov/project-details/7529414
关键词：
American Society of Clinical OncologyAngiogenesis InhibitorsAntineoplastic AgentsArchivesAreaAwardB-LymphocytesBiological MarkersBiopsyBreastCancer CenterCellsChairpersonCisplatinClinicClinicalClinical InvestigatorClinical ResearchClinical TrialsClinical Trials DesignCombination ChemotherapyComprehensive Cancer CenterConduct Clinical TrialsCorrelative StudyDataDevelopmentDevelopmental Therapeutics ProgramDiagnosisDiffuseDiseaseDisease-Free SurvivalDrug KineticsEastern Cooperative Oncology GroupEnd PointEnsureEpidermal Growth Factor ReceptorEtoposideExtensive StageFCGR3B geneFacultyFollicular LymphomaFundingGenesGenetic PolymorphismGroup MeetingsGuidelinesHematologic NeoplasmsHematologyHodgkin DiseaseImmune responseImmunohistochemistryInstitutionInternationalIrelandJointsK-Series Research Career ProgramsLaboratoriesLeadershipLimited StageLungLymphomaMS4A1 geneMalignant NeoplasmsMalignant neoplasm of lungManualsMedicineMedlone 21Mentored Clinical Oncology AwardMentored Clinical Scientist AwardMentored Patient-Oriented Research Career Development AwardMethodsMolecularMolecular ProfilingMonoclonal AntibodiesMonoclonal Antibody TherapyMultidrug Resistance GeneNon-Hodgkin&aposs LymphomaOperative Surgical ProceduresOralOutcomeParticipantPathway interactionsPatientsPeripheralPharmaceutical PreparationsPharmacology Shared ResourcePhasePhase I Clinical TrialsPhase I/II TrialPhase II Clinical TrialsPopulationPredictive FactorPredictive ValuePrincipal InvestigatorPrior TherapyPrognostic FactorProtein Tyrosine KinaseRadiationRadioimmunotherapyRefractoryRelapseResearchResearch ActivityResearch DesignResearch PersonnelResearch Project GrantsResource SharingRetrospective StudiesRoleSTAT3 geneScienceSiteSouthwest Oncology GroupStagingStem cell transplantStem cellsT-Cell LymphomaT-LymphocyteTestingTherapeuticTimeTissue MicroarrayTissuesTranslatingTranslational ResearchTranslational Research Shared ResourceUniversity HospitalsVascular Endothelial Growth FactorsWorkauthoritybasebevacizumabcancer pharmacologycancer research center directorchemotherapyclinical effectconceptdesigndrug developmentexperiencegemcitabineimprovedinhibitor/antagonistlapatiniblung small cell carcinomalymph nodesmacrophagemembermodel developmentnovelnovel therapeuticsoncologyprofessorprogramsprotocol developmentquality assuranceresponserituximabtositumomabtranslational studytumorigenesis

项目摘要

项目成果

FRANK M. TORTI的其他基金

相似基金

相关文献

中文摘要
翻译
建议两名工作人员调查员，都担任临床副助理主任的职务
英文摘要
Two staff investigators are proposed, both to serve in the function as Deputy Associate Directors for Clinical Research. Dr. Afshin Dowlati, an expert in novel therapeutic development in lung cancer, and Dr. John Sweetenham, an expert in lymphoma therapeutics, are both accomplished clinical investigators with considerable leadership capacity to coordinate clinical trials research emphasizing investigator-initiated efforts. As staff investigators, they will have focused time to devote to clinical trials development and oversight with special emphasis on investigator-initiated trials that cut across scientific programs and involve the Case CCC clinical trials disease teams. As staff investigators, they will have the prominence and authority to assist investigators in protocol development and design, and in efficient, safe management with a high degree of quality assurance during early phase drug development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting sideroflexin 4, a mitochondrial inner membrane protein involved iniron sulfur cluster biogenesis, to enhance the efficacy of DNA-damaging drugs inovarian cancer
Targeting sideroflexin 4, a mitochondrial inner membrane protein involved iniron sulfur cluster biogenesis, to enhance the efficacy of DNA-damaging drugs inovarian cancer
Targeting sideroflexin 4, a mitochondrial inner membrane protein involved iniron sulfur cluster biogenesis, to enhance the efficacy of DNA-damaging drugs inovarian cancer
Targeting sideroflexin 4, a mitochondrial inner membrane protein involved iniron sulfur cluster biogenesis, to enhance the efficacy of DNA-damaging drugs inovarian cancer
海外基金